Canadian SARS-CoV-2 serological survey using antenatal serum samples: a retrospective seroprevalence study
- DOI
- Language of the publication
- English
- Date
- 2023-04-04
- Type
- Article
- Author(s)
- Atkinson, Andrea
- Albert, Arianne
- McClymont, Elisabeth
- Andrade, Janice
- Beach, Lori
- Bolotin, Shelly
- Boucoiran, Isabelle
- Bullard, Jared
- Charlton, Carmen
- Crane, Joan
- Dougan, Shelley
- Forest, Jean-Claude
- German, Greg J.
- Giguère, Yves
- Girouard, Gabriel
- Hankins, Catherine
- Krajden, Mel
- Lang, Amanda
- Levett, Paul
- Minion, Jessica
- Neudorf, Cory
- Poliquin, Vanessa
- Robinson, Jason L.
- Scott, Heather
- Stein, Derek R.
- Tran, Vanessa
- Zahariadis, George
- Zhou, Hong Y.
- Money, Deborah
- The Antenatal Serostudies Team
- Publisher
- CMA Impact Inc.
Abstract
Background: Methods: Results: Interpretation:
Insufficient data on the rate and distribution of SARS-CoV-2 infection in Canada has presented a substantial challenge
to the public health response to the COVID-19 pandemic. Our objective was to assess SARS-CoV-2 seroprevalence in a representative sample of pregnant people throughout Canada, across multiple time points over 2 years of the pandemic, to describe the seroprevalence and show the ability of this process to provide prevalence estimates.
This Canadian retrospective serological surveillance study used existing serological prenatal samples across 10 provinces
over multiple time periods: Feb. 3–21, 2020; Aug. 24–Sept. 11, 2020; Nov. 16–Dec. 4, 2020; Nov. 15–Dec. 3, 2021; and results
from the province of British Columbia during a period in which the SARS-CoV-2 B.1.1.529 (Omicron) variant was predominant, from
Nov. 15, 2021, to June 11, 2022. Age and postal code administrative data allowed for comparison with concurrent polymerase
chain reactivity (PCR)–positive results collected by Statistics Canada and the Canadian Surveillance of COVID-19 in Pregnancy
(CANCOVID-Preg) project.
Seropositivity in antenatal serum as early as February 2020 indicates SARS-CoV-2 transmission before the World Health
Organization’s declaration of the pandemic. Seroprevalence in our sample of pregnant people was 1.84 to 8.90 times higher than the
recorded concurrent PCR-positive prevalence recorded among females aged 20–49 years in November–December 2020. Overall
seropositivity in our sample of pregnant people was low at the end of 2020, increasing to 15% in 1 province by the end of 2021. Seroprevalence among pregnant people in BC during the Omicron period increased from 5.8% to 43% from November 2021 to June 2022.
These results indicate widespread vulnerability to SARS-CoV-2 infection before vaccine availability in Canada. During the time periods sampled, public health tracking systems were under-reporting infections, and seroprevalence results during the
Omicron period indicate extensive community spread of SARS-CoV-2 infection.
Subject
- Health,
- Coronavirus diseases
Rights
Pagination
E305-E313
Peer review
Yes
Article
- Journal title
- CMAJ OPEN
- Journal volume
- 11
- Journal issue
- 2